Several years following FDA approval, Ibsrela® (tenapanor) oral tablets are now available to treat irritable bowel syndrome with constipation (IBS-C) in adults.

• Ibsrela is a first-in-class treatment for IBS-C that received FDA approval on September 12, 2019. However, manufacturer Ardelyx has only recently launched the product.
• Recommended dosing is 50mg taken twice daily by mouth: once immediately prior to breakfast or the first meal of the day, and once immediately prior to dinner.
• The wholesale acquisition cost (WAC) is $1,500 per 60 tablets.